| Literature DB >> 27259523 |
Zhivko Zhelev1, Rebecca Abbott1, Morwenna Rogers1, Simon Fleming2, Anthea Patterson2, William Trevor Hamilton1, Janet Heaton1, Jo Thompson Coon1, Bijay Vaidya3, Christopher Hyde4.
Abstract
OBJECTIVES: To evaluate the effectiveness of behaviour changing interventions targeting ordering of thyroid function tests.Entities:
Keywords: behaviour changing interventions; medical tests; systematic review; test ordering; thyroid function tests
Mesh:
Year: 2016 PMID: 27259523 PMCID: PMC4893867 DOI: 10.1136/bmjopen-2015-010065
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of the selection process.
Characteristics of the included studies
| Study and country | Study design | Setting | Targeted test users | Target tests | Thyroid tests |
|---|---|---|---|---|---|
| Adlan | Before and after; single site | Medical assessment unit (acutely ill hospital patients) | Physicians | TFTs only | TSH, FT4, FT3, TPOAb, TRAb |
| Baker | Cluster RCT | GP practices | GPs, locums, GPs in training and nurses | 5 frequently ordered laboratory tests suspected of being inappropriately ordered | TSH and FT4 |
| Berwick and Coltin, | Controlled cross-over; 3 sites | Ambulatory centres at health maintenance organisation | Internists and adult nurse practitioners | 13 laboratory and imaging tests suspected of being excessively ordered | TT4 |
| Chu | Before and after; single site | Adult tertiary referral teaching hospital ED | Interns and residents | Frequently ordered blood tests suspected of being excessively ordered | TFTs unspecified |
| Cipullo and Mostoufizadeh, | Before and after; single site | Community hospital | Medical staff (unspecified) | A range of high-volume laboratory procedures | TFTs unspecified but change in TT3 rate used as a measure of impact |
| Daucourt | Cluster RCT | General and psychiatric hospitals | Physicians | TFTs only | TSH, FT4, FT3, TRH test |
| Dowling | Before and after; single site | Innercity community health centre | Family practice residents | TSHs only (complete blood count with differential used as a comparator) | TSH |
| Emerson and Emerson, | Before and after; single site | University medical centre | Residents | All laboratory tests | TSH, FT3, FT4, TT3, TT4 (individual and cascade) |
| Feldkamp and Carey, | Before and after; single site | Metropolitan hospital and 22 satellite clinics (inpatients and outpatients) | Physicians | TFTs only | TSH, TT3, TT4 |
| Gama | Controlled study; single site | District general hospital (inpatients and outpatients) | General medicine physicians | All laboratory tests | TFTs unspecified |
| Grivell | Before and after; single site | Tertiary care community hospital | Consultants | 55 most commonly requested laboratory tests or test groups | TT4 |
| Hardwick | Before and after; multiple sites | All non-hospital-based laboratories in British Columbia | All users of non-hospital-based laboratories | TFTs only | TT3, TT4 |
| Horn | Interrupted time series with a parallel control group; multiple sites | Alliance of 5 multispecialty group practices | Primary care physicians | 27 laboratory tests | TSH |
| Larsson | Before and after; multiple sites | Primary healthcare centres | GPs and laboratory technicians | Various laboratory tests | TSH, FT4, TT4, TT3 |
| Nightingale | Before and after; single site | Supraregional liver unit at teaching hospital | House officers | Various laboratory tests | TSH |
| Rhyne and Gehlbach, | Before and after; single site | Family medicine centre | Physicians | TFTs only | Thyroid function panel including TT4 and TT3 |
| Schectman | Controlled study; single site | Primary care health maintenance organisation | Physicians, physician assistants and nurse practitioners | TFTs only | TSH, TT4, TT3 |
| Stuart | Before and after; single site | Urban public hospital ED | Consultants, registrars, junior medical officers and casual medical staff | All laboratory tests | TFTs unspecified |
| Thomas | Cluster RCT | Primary care practices in 1 NHS covered area | Family practitioners | 9 laboratory tests suspected of being inappropriately ordered | TSH |
| Tierney | RCT; single site | Academic general medicine practice | Physicians (residents and faculty) | 8 commonly ordered diagnostic tests | TSH |
| Tomlin | Controlled study; multiple sites | New Zealand primary care | All GPs on the New Zealand Medical Council's register compared with locum GPs and other medical specialists | TFTs only (but related programmes targeted inflammatory response tests and tests for infectious diarrhoea) | TSH, FT3, FT4 |
| Toubert | Before and after; single site | Teaching hospital | Physicians (various specialties, including endocrinologists) | TFTs only | TSH, FT3, FT4, TPOAb, TRAb, TgAb |
| van Gend | Before and after; multiple sites | GP practices in 1 geographical area | GPs | 15 laboratory tests | TSH, FT4 |
| van Walraven | Retrospective interrupted time series; multiple sites | All private non-hospital-based laboratories in Ontario | Physicians ordering tests from non-hospital laboratories | 7 laboratory tests; 6 unaffected tests were chosen as controls | TSH, TT4, TT3 |
| Vidal-Trécan | Before and after; multiple sites | A network of 50 non-profit university hospitals in the Paris region | Physicians | TFTs only | TSH, TT4, TT3, FT3, FT4 |
| Willis and Datta, | Before and after; single site | Medical admissions unit at a district general hospital | Nurses | Three potentially inappropriately requested test sets: thyroid profile, lipid profile and coagulation screen | Thyroid profile (unspecified) |
| Wong | Controlled study; single site | University teaching hospital | Physicians | TFTs, creatinine kinase and lactate dehydrogenase isoenzyme | TSH, TT4, TT3 |
ED, emergency department; FT3, free tri-iodothyronine; FT4, free thyroxine; GP, general practitioner; NHS, National Health Service; RCT, randomised controlled trial; TFTs, thyroid function tests; TgAb, thyroglobin antibody; TPOAb, thyroid peroxidase antibody; TRAb, thyrotropin receptor antibody; TRH, thyrotropin-releasing hormone test; TSH, thyroid-stimulating hormone; TT3, total tri-iodothyronine; TT4, total thyroxin.
Characteristics of the included studies: interventions
| Study and country | Setting | Educational programmes | Guidelines and protocols | Changes to funding | Reminders | Decision tools | Audit and feedback |
|---|---|---|---|---|---|---|---|
| Single-mechanism interventions | |||||||
| Adlan | Hospital | X | |||||
| Berwick and Coltin, | Primary care | X | XX | ||||
| Chu | Hospital | X | |||||
| Cipullo and Mostoufizadeh, | Hospital | X | |||||
| Daucourt | Hospital | X | X | ||||
| Emerson and Emerson, | Primary care | X | |||||
| Feldkamp and Carey, | Hospital | X | |||||
| Gama | Hospital | X | |||||
| Grivell | Hospital | X | |||||
| Horn | Primary care | X | |||||
| Larsson | Primary care | X | |||||
| Schectman | Primary care | X | |||||
| Tierney | Primary care | X | |||||
| Thomas | Primary care | X | |||||
| Multifaceted interventions | |||||||
| Baker | Primary care | X | X | ||||
| Daucourt | Hospital | X | X | ||||
| Dowling | Primary care | X | X | ||||
| Hardwick | Primary care | X | X | ||||
| Nightingale | Hospital | X | X | X | |||
| Rhyne and Gehlbach, | Primary care | X | X | ||||
| Schectman | Primary care | X | X | X | |||
| Stuart | Hospital | X | X | X | |||
| Thomas | Primary care | X | X | ||||
| Tomlin | Primary care | X | X | X | |||
| Toubert | Hospital | X | X | ||||
| van Gend | Primary care | X | X | ||||
| van Walraven | Primary care | X | X | X | |||
| Vidal-Trécan | Hospital | X | X | X | |||
| Willis and Datta, | Hospital | X | X | ||||
| Wong | Hospital | X | X | ||||
XX—two independent interventions of the same type.
*Study comparing directly two alternative interventions (Schectman et al33 had a non-comparative single-intervention design in its first phase and a multifaceted comparative design in the second phase; Thomas et al10 compared a single-mechanism (reminders) vs multifaceted (feedback plus reminders) interventions; Daucourt et al25 compared two single-mechanism interventions with their combination and usual practice defined as simple diffusion of guidelines).
Summary of results: effectiveness of the interventions with respect to thyroid function tests
| Outcome | Study | Intervention | Direction | Large effect | Statistically significant change | RCT design | Notes on outcome measures | |
|---|---|---|---|---|---|---|---|---|
| Single-mechanism interventions | ||||||||
| Test numbers or rates | Adlan | Guidelines | + | + | + | − | Per cent admissions offered TFTs | |
| Berwick and Coltin | Education (test specific) | + | − | NR | − | Per 100 encounters | ||
| Berwick and Coltin | Feedback on cost | + | − | NR | − | Per 100 encounters | ||
| Berwick and Coltin | Feedback on yield | − | + | NR | − | Per 100 encounters | ||
| Chu | Guidelines | + | + | + | − | Per 100 ED visits | ||
| Cipullo and Mostoufizadeh | Guidelines | + | − | NR | − | Per discharge | ||
| Gama | Feedback | + | + | + | − | Per outpatient visit | ||
| Emerson and Emerson | Request form redesign | + | − | + | − | |||
| Feldkamp and Carey | Guidelines | + | − | NR | − | Per 1000 patients | ||
| Grivell | Feedback | − | + | NR | − | |||
| Horn | Display of cost of tests being ordered | + | − | − | − | Per 1000 visits | ||
| Schectman | Educational memorandum | + | − | + | − | Per patient | ||
| Thomas | Feedback | + | − | + | + | Per 10 000 registered patients | ||
| Thomas | Reminders | + | − | + | + | Per 10 000 registered patients | ||
| Appropriateness (compliance) | Daucourt | Pocket memory card | + | − | − | + | Proportion of TFTs ordered in accordance with the guidelines | |
| Daucourt | Request form redesign | + | + | + | + | Proportion of TFTs ordered in accordance with the guidelines | ||
| Schectman | Educational memorandum | + | + | + | − | Compliance with TSH-only strategy | ||
| Schectman | Reminders | + | − | + | − | Compliance with TSH-only strategy | ||
| Expenditure | Tierney | Display of | + | − | − | + | Per visit | |
| CV | Berwick and Coltin | Education (test specific) | − | − | NR | − | ||
| Berwick and Coltin | Feedback on cost | + | + | NR | − | |||
| Berwick and Coltin | Feedback on yield | + | + | NR | − | |||
| Pattern | Emerson and Emerson | Request form redesign | + | + | NR | − | Sought to shift to TSH and thyroid cascade | |
| Feldkamp and Carey | Guidelines | + | + | NR | − | Sought to shift to TSH and TSH-based algorithm | ||
| Larsson | Years 1–2 | Education | + | − | + | − | Sought to shift to TSH; and reduce ordering of TT3 and FT4 relative to TSH. Summary based on TSH/all TFTs ratios | |
| Larsson | Years 2–6 | Education | − | − | + | − | Sought to shift to TSH; and reduce ordering of TT3 and FT4 relative to TSH. Summary based on TSH/all TFTs ratios | |
| Multiple-mechanism interventions | ||||||||
| Test numbers or rates | Baker | Education and guidelines | + | − | − | + | Per 1000 registered patients | |
| Daucourt | Pocket memory card and request form redesign | + | − | + | + | Proportion of TFTs ordered in accordance with the guidelines | ||
| Dowling | Education and feedback | + | − | + | − | Per patient visit | ||
| Hardwick | Funding policy and guidelines | + | − | NR | − | |||
| Rhyne and Gehlbach | Education and guidelines | + | + | + | − | Per 100 encounters | ||
| Schectman | Feedback and reminders | + | − | + | − | Per patient | ||
| Thomas | Feedback and reminders | + | − | + | + | Per 10 000 registered patients | ||
| Tomlin | Education and feedback and guidelines | + | + | + | − | Per year per GP | ||
| Toubert | Guidelines and reminders | + | + | NR | − | |||
| van Walraven | Guidelines and funding policy | + | + | + | − | Summary based on decrease in the proportion of TT4 and T3RU | ||
| van Walraven | Guidelines and request form redesign | + | − | + | − | Summary based on decrease in TSH utilisation | ||
| Vidal-Trécan | Education and guidelines and request form redesign | + | − | NR | − | Summary based on the total number of TFTs | ||
| Willis and Datta | Education and guidelines | + | + | + | − | Per admission | ||
| Wong | Guidelines and request form redesign | + | + | NR | − | |||
| Appropriateness (compliance) | Dowling | Education and feedback | + | + | + | − | Per cent TSH indicated | |
| Nightingale | Education and feedback and protocol management system | + | + | NR | − | Per cent patients requiring a particular investigation according to protocol who were actually tested | ||
| Rhyne and Gehlbach | Education and guidelines | + | − | − | − | Per cent ‘high’ and ‘low’ indications | ||
| Schectman | Feedback and reminders | + | − | − | − | |||
| Toubert | Guidelines and reminders | + | + | + | − | Per cent appropriate | ||
| Expenditure | Hardwick | Funding policy and guidelines | + | + | NR | − | ||
| Stuart | Education and feedback and guidelines | + | + | + | − | |||
| Tomlin | Education and feedback and guidelines | + | − | NR | − | |||
| Pattern | Hardwick | Funding policy and guidelines | + | − | NR | − | Sought to decrease proportion of TT3 as TFTs requested. Summary based on per cent of TFTs TT3 | |
| Tomlin | Education and feedback and guidelines | + | + | + | − | Sought to shift to TSH. Summary based on per cent TFTs TSH alone | ||
| Toubert | Guidelines and reminders | + | + | NR | − | Sought to shift to TSH. Summary based on per cent TFTs TSH alone | ||
| van Gend | Feedback and test form redesign | + | + | NR | − | Sought to shift away from TT4. Summary based on FT4:TSH ratio | ||
| Vidal-Trecan | Education and guidelines and request form redesign | + | − | NR | − | Sought to shift to TSH. Summary based on the proportion of FT3 and TSH | ||
| Wong | Guidelines and request form redesign | + | + | NR | − | Sought to decrease ordering of ‘complete’ thyroid panel to more selective use of individual tests | ||
Direction: ‘+’ indicates result favours behaviour change intervention; ‘−’ opposite. Large effect: ‘+’ indicates risk difference is ≥20%; ‘−’ <20%. Statistically significant change: ‘+’ indicates 95% CI do not include no effect or p<0.05; ‘−’ opposite. RCT design: ‘+’ indicates study design is RCT; ‘−’ not RCT.
CV, coefficient of variation; ED, emergency department; FT3, free tri-iodothyronine; FT4, free thyroxine; GP, general practitioner; NR, indicates item not reported; RCT, randomised controlled trial; T3RU, tri-iodothyronine resin uptake; TFTs, thyroid function tests; TSH, thyroid-stimulating hormone; TT3, total tri-iodothyronine; TT4, total thyroxin.
Summary of results: additional information
| Study and country | N at baseline | Intervention and outcome measure | Level at baseline | Level postintervention | Effect on outcome | |
|---|---|---|---|---|---|---|
| Randomised controlled study designs | ||||||
| Baker | Practices: | 17.4 (8.0, 39.5) (I) | 19.8 (6.2, 42.3) (I) at 6 months |
For TFTs, the difference in mean change in test rate from baseline to 4th quarter was—1.45 in favour of the I (95% CI −4.59 to 1.68) but was not statistically significant (p=0.35) The intervention had no significant effect on the other tests, too. | ||
| Daucourt | Hospital wards:
17 (PMC+TRF) 20 (TRF) 17 (MPC) 13 (C) | NA | 77.9% (95% CI 68.9% to 87.0%) (MPC+TRF) |
GCR was significantly higher in PMC+TRF compared with the C (OR 2.65; 95% CI 1.52 to 4.62; p<0.01); slightly lower compared with TRF and slightly higher compared with MPC but the differences were not statistically significant No difference between MPC and the C (OR 1.28; 95% CI 0.75 to 2.19; p=0.37) | ||
| Thomas | Practices:
21 (FB+R) 22 (FB) 22 (R) 20 (C) | 750 (515–1329) (C) | 795 (552–1466) (C) |
Is were significantly less likely to request TFTs (FB group: OR 0.90 (0.84 to 0.97), p=0.005; R group: OR 0.82 (0.83–0.95), p=0.001). Across all targeted tests, intervention practices were significantly less likely to order tests. | ||
| Tierney | Scheduled visits:
7658 (I) 7590 (C) | NA | 1.25 (C) |
TSH showed 10.3% decrease in charges per visit in the I group but this difference was not significant at p=0.05. Across all targeted tests, there was a significant reduction in charges per visit (−8.8%, p<0.05), with return to baseline at 3 months follow-up. | ||
| Non-randomised controlled study designs | ||||||
| Berwick and Coltin, | 35 internists and 30 adult nurses at 3 centres (total number of visits not given) | TT4 tests per 100 encounters:
Site X: 72 Site Y: 72 Site Z: 45 Site X: 40–273 Site Y: 36–122 Site Z: 35–78 |
TT4 use declined in the TSE and FBC groups but increased in FBY; CV decreased in FBC and FBY but increased in the C group and showed very small increase in TSE group. The statistical significance of these results is NR. Across all tests statistically significant decline in test ordering (14.2%, p=0.012) was observed only in the FBC group. | |||
| C: +1.7% | +15.7% | |||||
| TSE: −15.9% | +0.5% | |||||
| FBC: −12.1% | −23.6 | |||||
| FBY: +34.0% | −28.2 | |||||
| Gama | Outpatient visits:
2991 (I) 4393 (C) | 0.17 (0.12–0.22) (I) | 0.13 (0.11–0.17) (I) |
The mean number of TFTs per outpatient visit decreased by 21.9% in the I group (p<0.01) and increase by 20.8% (not significant) in the C group. Similar results were obtained for the other tests for outpatients but not for inpatients (data NR). | ||
| Schectman | 1425 patients, 30 clinicians (group distribution not given) | 68% (R) | 81% (R) at 6 months |
Significant increase in compliance in the reminder group (p=0.05) but not in the R+FB group; however, after excluding an outlier both groups had similar increase in compliance (77% vs 80%, p=0.39). The mean number of TFTs ordered per patient also decreased significantly (no p value given) but increased again at 1-year follow-up (only data combining both groups provided). TSH levels increased significantly while TT4 and T3RU decreased but no details are given. | ||
| Tomlin | GPs:
3140 (I) 2443 (C) |
TSH: FT4: FT3: Total number of TFTs: Ratios of different TFTs:
TSH/FT4 TSH/FT3 Expenditure (%) | 223.6 (I) | 215.2 (I) | TSH showed small decrease (4%, p<0.01) in the I group and no change in the C group (p<0.11). | |
| Wong | NR | 9 months : 1100 6 months: 1150 3 months: 1100 9 months: 900 6 months: 1300 3 months: 900 9 months: 950 6 months: 1000 3 months: 900 9 months: 1000 6 months: 980 3 months: 980 9 months: 650 6 months: 700 3 months: 750 | At 2 months: 1000 4 months: 1000 6 months:1100 8 months:950 2 months: 500 4 months: 500 6 months:600 8 months:500 2 months: 200 4 months: 300 6 months: 400 8 months: 300 2 months: 1100 4 months: 700 6 months:1000 2 months: 700 4 months: 500 6 months:700 | Distributing guidelines through a bulletin alone failed to produce effect but in combination with request form redesign it led to restructuring of test ordering patterns with decrease of ‘complete’ thyroid panel and increase of hyperthyroid and hypothyroid panels and thyroid function screen. | ||
| Interrupted time series | ||||||
| Horn | Average monthly orders per 1000 patient visits (TSH):
174.1 (I) 140.3 (C) | 0.2% (I) 0.1% (C) | 0.5% decrease (I) 0.4% increase (C) | The difference in the rate of change preintervention to postintervention was 0.7% decrease in the I group and 0.3% increase in the C group; none of these results was significant at p value <0.002 (2-sided Bonferroni-adjusted p value). | ||
| Van Walraven | NR | TSH: 1 per 100 persons* TT4: 1.2 per 100 persons* | TT4: 4359 (95% CI −14 to 23 430) tests avoided T3RU: 3073 (−28 to 18 153) tests avoided TSH: 2200 (95% CI −1638 to 6039) tests avoided | G+CFP led to 96% decrease in the TT4 utilisation (p=0.02) and decrease in T3RU. | ||
| Before and after study designs | ||||||
| Adlan | Admissions:
1593 (pre) 1176 (post) | 53.8% (857 out of 1593) | 21.7% (255 out of 1176) | Significant reduction (32.1%, p<0.001) in the proportion of admitted patients offered TFTs | ||
| Chu | ED visits:
24 652 (pre) 25 576 (post) | 2.2 (20-week preintervention period) | 1.6 (20-week postintervention period) | Significant reduction in the mean number of TFTs (0.6 tests per 100 ED presentations, p=0.001) | ||
| Cipullo and Mostoufizadeh, | NA | 0.006 (1 year before) | 0.005 | The number of T3 uptake per discharge decreased by 17%. | ||
| Dowling | Patient visits: | 28% (25 of 90) | 65% (15 of 23) | The proportion of indicated TSHs increased significantly (p<0.001) while TSHs per patient visit decreased significantly (p<0.0001) in the intervention period but both showed some decline at 5 months follow-up. | ||
| Emerson and Emerson, | Unclear | TSH: 5300* | TSH: 3000* | TFT testing decreased significantly (p<0.01) with a shift towards FT4 and thyroid cascade. | ||
| Feldkamp and Carey, | Sequential TFT requests: | ‘TSH only’ and DRTSH accounted for 92.4% of all TFTs 3 years after the introduction of the algorithm. The other combinations gradually decreased. However, the statistical significance of these results is NR. | ||||
| TFT only | 33.3% | 44.8% | 32.2% | |||
| DRTSH algorithm | – | 24.4% | 60.2% | |||
| TSH+TT4+T3RU | 16.6% | 3.9% | 1.3% | |||
| TT4 only | 10.0% | 4.8% | 0.8% | |||
| TT4+T3RU | 6.8% | 2.8% | 1.1% | |||
| Others (including TT3) | – | – | 3.0% | |||
| TFTs per 1000 patients: | Prealgorithm: | Postalgorithm: | Tests/1000 | |||
| TSH | 832 | 982 | 1000 | |||
| TT4 | 667 | 216 | 202 | |||
| T3RU | 234 | 159 | 202 | |||
| Total | 1 733 | 1359 | 1404 | |||
| Difference | – | 374 | 329 | |||
| Grivell | NR | NA | 1.20 | Thyroxin requests in the postintervention period were 1.2 times the requests in the preintervention period but the statistical significance of this result was NR. | ||
| Hardwick | NR | Overall decline from baseline to 3 years postintervention (1978/79) with shift towards TT4 which accounted for 80.4% of all TFT investigations in the last period. | ||||
| TT3 | 21.8% (29 004) | 19.0% (35 101) | 4.7% (7502) | |||
| TT4 | 51.8% (68 912) | 50.8% (93 988) | 80.4% (128 343) | |||
| ETR | 26.4% (35 183) | 30.2% (55 798) | 14.9% (23 703) | |||
| Total | 100% (133 099) | 100% (184 887) | 100% (159 548) | |||
| TT3 | 20.4% (33 334) | 11.8% (19 255) | ||||
| TT4 | 49.6% (81 004) | 62.3% (101 805) | ||||
| ETR | 29.8% (48 832) | 25.9% (42 346) | ||||
| Total | 100% (163 170) | 100% (163 406) | ||||
| Horn | Physicians: | 174.1 (I) 140.3 (C) 0.2% (I) 0.1% (C) | −0.5% (I) 0.4% (C) | −0.7% (I) 0.3% (C) | Monthly order rates for TSH decreased slightly in the I group and increased in the C group but the difference was not statistically significant (p=0.04; because 27 tests were analysed, the study used a 2-sided Bonferroni-adjusted p value of <0.002 to determine statistical significance). | |
| Larsson | 19 primary care centres | Significant decrease in TT3/TSH (difference between mean ratios 0.073, SD=0.089, p=0.0012) and non-significant decrease in FT4/TSH (difference 0.032, SD=0.116, p=0.13). | ||||
| TT3/TSH | 0.129 | 0.056 | ||||
| FT4/TSH | 0.333 | 0.301 | ||||
| TSH/total number of TFTs | 0.124 | 0.141 | ||||
| Mindemarkand Larsson | Median ratios: | 7 years after the intervention TT3/TSH and (TT4+FT4)/TSH were not significantly different from those at the end of the original study period, thus showing no decay in the intervention's effect. However, THS/all TFTs showed slight decrease (difference −0.043) which was statistically significant (p<0.05). | ||||
| TT3/TSH | 0.029 | 0.022 | ||||
| (TT4+FT4)/TSH | 0.273 | 0.237 | ||||
| TSH/all TFTs | 0.115 | 0.072 | ||||
| Nightingale | Number of patients: 654 (before) 833 (after) | 55%* | 85%* | Compliance of TSH requests increased but results are given only as a graph and the statistical significance is NR. | ||
| Rhyne and Gehlbach, | NR | TFPs per 100 encounters Proportion of: ‘high indications’ ‘low indications’ | Significant decrease in the number of TFP ordered per encounter in the 3 months after the intervention (p<0.05) but return to baseline in the following 3 months. Results given only as a graph. The proportion of FTP for ‘high indications’ increased and that for ‘low indications’ decreased but was not statistically significant (p<0.05). Senior residents decreased their TFP ordering rate while that of junior residents increased (p<0.05). | |||
| Schectman | 1425 patients, | 35% | 67% at 2 months (following EM) |
Significant increase in compliance after EM (p<0.0001) The mean number of TFTs ordered per patient decreased significantly following EM (p<0.0001) and showed further decline at 6 months after the subsequent interventions ( The educational intervention had greater impact on nurses and physician assistants than physicians (absolute increase in compliance 63% vs 28%). | ||
| Stuart | NR; annual census of 42 500 patients | 0.426 | 0.047 | TFT ordering decreased by 89% and showed a significant decrease in cost per patient (−89% difference (95% CI −55% to −123%; p<0.001). | ||
| Toubert | 800-bed hospital with annual census of 25 266 inpatients and 242 013 outpatients | A substantial decrease in the total number of TFTs mainly due to a decrease in the number of FT3 and FT4; a decrease in the relative proportion of FT3. Single TSH order forms increased from 23% to 50%, while TSH+FT4+FT3 decreased. The statistical significance of these results was NR. | ||||
| Total TSH tests | 1329 | 1119 | 1062 | |||
| Total FT4 tests | 1011 | 535 | 539 | |||
| Total FT3 tests | 715 | 247 | 226 | |||
| Total number of TFTs | 3145 | 1901 | 1827 | |||
| Patterns: | ||||||
| Single TSH | 305 | 563 | 512 | |||
| TSH+FT4 | 319 | 313 | 333 | |||
| TSH+FT3 | 23 | 25 | 20 | |||
| TSH+FT4+FT3 | 682 | 218 | 197 | |||
| FT4+FT3 | 10 | 4 | 9 | |||
| All TFT request forms | 1339 | 1123 | 1071 | |||
| Appropriateness: | 42.5% | 72.4% | 70.7% | |||
| van Gend | NR | There was a decrease in the FT4:TSH ratio indicating that the intervention had impact on test ordering patterns but the statistical significance of the results was NR. | ||||
| Vidal-Trécan | 11% decrease in the total number of TFTs even though the number of admissions increased by 2% and the number of outpatient visits by 6%. | |||||
| Total TFTs | 100% (27 945) | 88.7% (24 794) | ||||
| FT3 | 20% (5491) | 14% (3534 of 24 794) | ||||
| TT3 | 1% (339) | 1% (371 of 24 794) | ||||
| FT4 | 33% (9301) | 33% (8125 of 24 794) | ||||
| TT4 | 2% (478) | 1% (238 of 24 794) | ||||
| TSH | 44% (12 336) | 51% (12 526 of 24 794) | ||||
| Willis and Datta, | An average of 950 patients and 309 thyroid profiles per month | 0.32 (0.05) | 0.08 (0.01) | Significant decrease in the number of requested thyroid profiles (p<0.001). | ||
*Approximate reading off a graph.
C, control group; CBC, complete blood count; CFP, changes to funding policy; CK, creatinine kinase; CV, coefficient of variation; DRTSH, directed thyroid testing algorithm; E, education; ED,emergency department; EM, educational memorandum; ETR, effective thyroxin ratio; FB, feedback; FBC, feedback on cost; FBY, feedback on yield; FT3, free tri-iodothyronine; FT4, free thyroxine; FTI, free thyroid index; G, guidelines/protocol; GCR, guideline conformity rate, the proportion of TFTs ordered in accordance with the guidelines; GP, general practitioner; I, Intervention group; LDH, lactic dehydrogenase isoenzyme; NA, not available; NR, not reported; PMC, pocket memory card; PMS, protocol management system; R, reminders; T3 (RIA), tri-iodothyronine radioimmunoassay; T3RU, tri-iodothyronine resin uptake; T4 (RIA), thyroxin radioimmunoassay; TFP, thyroid function panel; TFTs, thyroid function tests; TRF, test request form redesign; TSE, test-specific education; TSH, thyroid-stimulating hormone; TT3, total tri-iodothyronine; TT4, total thyroxin.
Results from the methodological quality assessment of the included studies using the EPHPP tool
| Study | Selection bias | Study design | Confounders | Blinding | Data collection method | Withdrawals and dropouts | Global rating |
|---|---|---|---|---|---|---|---|
| Randomised controlled trials | |||||||
| Baker | Strong | Strong | Strong | Moderate | Strong | Strong | Strong |
| Daucourt | Moderate | Strong | Strong | Strong | Moderate | Strong | Strong |
| Thomas | Strong | Strong | Strong | Strong | Strong | Strong | Strong |
| Tierney | Strong | Strong | Strong | Moderate | Strong | Strong | Strong |
| Non-randomised controlled studies | |||||||
| Berwick and Coltin | Moderate | Strong | Moderate | Weak | Strong | Weak | Weak |
| Gama | Weak | Moderate | Weak | Weak | Strong | Strong | Weak |
| Schectman | Moderate | Strong | Weak | Moderate | Strong | Strong | Moderate |
| Tomlin | Strong | Strong | Weak | Moderate | Strong | Moderate | Moderate |
| Wong | Weak | Moderate | Weak | Moderate | Strong | Weak | Weak |
| Interrupted time series | |||||||
| Horn | Moderate | Moderate | Moderate | Weak | Strong | Moderate | Moderate |
| van Walraven | Strong | Moderate | Moderate | Strong | Strong | Strong | Strong |
| Before and after studies | |||||||
| Adlan | Weak | Moderate | Weak | Moderate | Strong | Weak | Weak |
| Chu | Weak | Moderate | Weak | Moderate | Strong | Weak | Weak |
| Cipullo and Mostoufizadeh | Weak | Moderate | Weak | Weak | Weak | Weak | Weak |
| Dowling | Weak | Moderate | Weak | Weak | Weak | Strong | Weak |
| Emerson and Emerson | Weak | Moderate | Weak | Weak | Strong | Weak | Weak |
| Feldkamp and Carey | Weak | Moderate | Weak | Weak | Strong | Weak | Weak |
| Grivell | Weak | Moderate | Weak | Weak | Strong | Weak | Weak |
| Hardwick | Strong | Moderate | Moderate | Strong | Strong | Strong | Moderate |
| Larsson | Moderate | Moderate | Weak | Moderate | Strong | Strong | Moderate |
| Nightingale | Weak | Moderate | Weak | Weak | Strong | Weak | Weak |
| Rhyne and Gehlbach | Weak | Moderate | Weak | Moderate | Strong | Weak | Weak |
| Stuart | Weak | Moderate | Weak | Moderate | Moderate | Moderate | Weak |
| Toubert | Weak | Moderate | Weak | Moderate | Moderate | Weak | Weak |
| van Gend | Strong | Moderate | Weak | Moderate | Strong | Strong | Moderate |
| Vidal-Trécan | Moderate | Moderate | Moderate | Moderate | Strong | Strong | Strong |
| Willis and Datta | Weak | Moderate | Weak | Moderate | Strong | Weak | Weak |